ImmuCell Corporation
An entrepreneurial animal health company that develops, manufactures and markets scientifically-proven products that maximize the genetic potential of dairy and beef through disease prevention, and reduced dependence on antibiotics.
- Healthcare
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $3.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 5 % | 25 % | 12 % | 25 % | (4 %) | (6 %) | 52 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 1 % | (7 %) | (9 %) | 1 % | (12 %) | (17 %) | 4 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (21 %) | (9 %) | (7 %) | - | (13 %) | (33 %) | (8 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 32 % | 27 % | 28 % | 22 % | 24 % | 25 % | 15 % |
Source: Company filings or news article
Related Content
ImmuCell Corporation is a specialized animal health company focused on improving the health and productivity of dairy and beef industries. The company develops, manufactures, and markets the First Defense product line, which provides immediate protection against aggressive pathogens such as E. coli, coronavirus, and rotavirus in newborn dairy and beef calves. This unique product is derived from colostrum and is the only USDA-accredited scours preventative that does not rely on traditional antibiotics. ImmuCell serves dairy and beef producers, offering cost-effective solutions to maximize the health and welfare of their calves and milk-producing cows. The company operates in the animal health market, adhering to stringent standards set by USDA, CFIA, FDA, and OMRI. ImmuCell's business model revolves around the development and commercialization of its proprietary products, generating revenue through direct sales to its target market. The company prides itself on running a lean operation, focusing on efficacy and customer commitment without inflating prices due to bureaucratic overhead.
Keywords: animal health, dairy industry, beef industry, colostrum-derived, scours prevention, E. coli, coronavirus, rotavirus, USDA-accredited, cost-effective solutions.